Amphora Improves Cell-Based Screening of Caliper System; Caliper Purchases Rights | GenomeWeb

In a move expected to strengthen its cell-based assay offerings on its LabChip microfluidics system, Caliper Life Sciences, of Hopkinton, Mass., earlier this month agreed to acquire cell culture and other technology developed by Amphora Discovery, of Research Triangle Park, NC.

Caliper said it will now incorporate the technology into a new calcium-flux assay, which will enable users of the LabChip to perform assays against G-protein coupled receptors — one of the more important cellular targets in drug screening.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.